LNFP I (Lacto-N-fucopentaose I) is a highly abundant, α1-2 fucosylated HMO in human milk. Some primary known benefits of LNFP I include modulation of the immune system, binding of toxins, and positively supporting gut health by selectively stimulating bifidobacteria.
GlyCare™ LNFP I is presently undergoing development
HMO help support immunity. Clinical studies have reported a relationship between HMO and immune outcomes in infants. HMO are reported to support an infant’s immune system. HMO may help reduce the risk of infection.
Clinical data suggest HMOs support intestinal health in infants. Preclinical and clinical data indicate that HMOs support the growth of beneficial bacteria/bifidobacteria. HMOs may help support the growth of beneficial bacteria/bifidobacteria which are believed to be important for immune and intestinal development and health.
Emerging data from pre-clinical models and breast milk studies suggest that HMOs may play a role reducing the incidence of certain allergic manifestations.